956 results on '"Shuch, Brian"'
Search Results
152. Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma
153. CLINICAL FEATURES AND MANAGEMENT OF HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER (HLRCC): 2008
154. Pathologic validation of renal cell carcinoma histology in the Surveillance, Epidemiology, and End Results program
155. Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
156. Surgical management of large renal tumors
157. Quality of pathological reporting for renal cell cancer: implications for systemic therapy, prognostication and surveillance
158. Predictive Factors for Malignant Pheochromocytoma: Analysis of 136 Patients
159. Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality?
160. Immunological therapy in urological malignancy: Novel combination strategies
161. Pathological, Immunohistochemical and Cytogenetic Features of Papillary Renal Cell Carcinoma With Clear Cell Features
162. Ultrasound-based combination therapy: potential in urologic cancer
163. Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma
164. Radiomic Features and Machine Learning for the Discrimination of Renal Tumor Histological Subtypes: A Pragmatic Study Using Clinical-Routine Computed Tomography
165. Transcriptomics in RCC
166. Reply by Authors
167. Sporadic Angiomyolipomas Growth Kinetics While on Everolimus: Results of a Phase II Trial
168. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021
169. Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.
170. Minimally invasive partial nephrectomy versus percutaneous cryoablation for stage Ia renal cell carcinoma: A cost-effectiveness analysis.
171. Clinically advanced renal cell carcinoma (RCC) and renal sarcoma (RSC) in young patients: A comprehensive genomic profiling (CGP) study.
172. PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).
173. Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer
174. PD11-11 SURVEILLANCE AND COMMUNICATION OF SURGICAL RESULTS IN LOCALIZED RENAL CELL CARCINOMA, RESULTS FROM A LARGE INTERNATIONAL PATIENT SURVEY
175. MP50-20 CLINICAL CONSENSUS STATEMENT
176. Fear of cancer recurrence among patients and survivors diagnosed with localized renal cell carcinoma.
177. Genetic risk assessment for hereditary RCC: Report from the consensus panel meeting.
178. Complications of Adrenal Surgery
179. Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma
180. Contemporary Management of Renal Tumors With Venous Tumor Thrombus
181. Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights
182. Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy
183. VALIDATION OF CA-IX POLYMORPHISM RS12553173 AS AN INDEPENDENT PROGNOSTIC FACTOR OF OVERALL SURVIVAL IN METASTATIC CLEAR CELL RENAL CELL CARCINOMA: 1792
184. Presence of Tumor Necrosis is Not a Significant Predictor of Survival in Clear Cell Renal Cell Carcinoma: Higher Prognostic Accuracy of Extent Based Rather Than Presence/Absence Classification
185. Editorial Comment
186. Intraoperative Thrombus Embolization During Nephrectomy and Tumor Thrombectomy: Critical Analysis of the University of California-Los Angeles Experience
187. SERUM LEVELS OF SHED HER2/NEU PROTEIN IN MEN WITH PROSTATE CANCER CORRELATE WITH DISEASE PROGRESSION
188. Decisional Regret and Financial Toxicity among Patients with Benign Renal Masses.
189. Cancer-Specific Survival Outcomes Among Patients Treated During the Cytokine Era of Kidney Cancer (1989–2005): A Benchmark for Emerging Targeted Cancer Therapies
190. Brain Metastasis From Renal Cell Carcinoma: Presentation, Recurrence, and Survival
191. Performance Status and Cytoreductive Nephrectomy: Redefining Management in Patients With Poor Performance
192. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm
193. Serum Carbonic Anhydrase 9 Level is Associated With Postoperative Recurrence of Conventional Renal Cell Cancer
194. Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies
195. MOLECULAR PROGNOSTIC TUMOR PROFILING OF TYPE 1 AND TYPE 2 PAPILLARY RENAL CELL CARCINOMA: RELEVANCE TO THE DEVELOPMENT OF TUMOR-SPECIFIC TARGETED THERAPIES: 605
196. GENDER SPECIFIC CYTOGENETIC SIGNATURES CAN DISTINGUISH BETWEEN ONCOCYTOMA AND CHROMOPHOBE RENAL CELL CARCINOMA: 479
197. PAPILLARY RENAL CELL CARCINOMA WITH CLEAR CELLS – PATHOLOGICAL, IMMUNOHISTOCHEMICAL AND CYTOGENETIC CHARACTERISTICS OF A NOVEL ENTITY: 480
198. Prognostic Factors for Renal Cell Carcinoma With Tumor Thrombus Extension
199. Harnessing the Genomic Landscape of the Small Renal Mass to Guide Clinical Management
200. Racial Disparity of Epidermal Growth Factor Receptor Expression in Prostate Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.